Equivalent efficacies of reverse hybrid and concomitant therapies in first‐line treatment of <scp><i>Helicobacter pylori</i></scp> infection

Abstract

Fourteen-day reverse hybrid therapy and 14-day concomitant therapy are equivalent in efficacy for the first-line treatment of H. pylori infection. However, reverse hybrid therapy has fewer adverse events compared with concomitant therapy.